Asian patients. Unexplained, persistent proteinuria during routine urinalysis testing. Predisposing factors for myopathy/rhabdomyolysis (eg, renal impairment, hypothyroidism, personal or family history of hereditary muscular disorders, history of muscular toxicity w/ other HMG-CoA reductase inhibitors, fibrates or niacin, alcohol abuse, situations where increased plasma levels occur & concomitant use of fibrates or niacin). Measure creatinine kinase levels in patients who report inexplicable muscle pain, weakness or cramps particularly if associated w/ malaise or fever. Temporarily w/hold in patients w/ acute serious conditions suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine & electrolyte disorders; or uncontrolled seizures). Increased HbA1c & serum glucose levels. Excessive alcohol consumption &/or history of liver disease. Increasing the dose to 40 mg should only be reserved for patients w/ severe hypercholesterolaemia at high CV risk who do not achieve their treatment goal on 20 mg & should only be initiated under close specialist supervision. Concomitant use of various PI. Limit to max 10 mg/day dose if combined w/ fibrates or lipid-lowering doses of niacin (≥1 g/day). May affect ability to drive or operate machinery. Moderate & severe hepatic impairment. The evaluation of linear growth, wt, BMI & secondary characteristics of sexual maturation by Tanner staging in childn & adolescents 10-17 yr taking rosuvastatin is limited to 1-yr period. Elderly ≥65 yr.